CHA News

CHA Comments on Proposed Payment Model to Lower Prescription Drug Costs

This post has been archived and contains information that may be out of date.

CHA has submitted comments to the Center for Medicare & Medicaid Innovation in response to its anticipated Accelerating Clinical Evidence (ACE) model.  

The ACE model would adjust Medicare Part B payment amounts for accelerated approval program drugs to give manufacturers an incentive to expedite and complete confirmatory clinical trials.  CMS did not include a timeline for when the model will begin.